BBIO News and Press, BridgeBio Pharma Inc. From 11/09/22

PALO ALTO, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of the management team wi...

BridgeBio Pharma press release ( NASDAQ: BBIO ): Q3 GAAP EPS of -$0.93 beats by $0.06 . Revenue of $0.34M (-85.5% Y/Y) misses by $4.33M . Cash, cash equivalents and marketable securities, excluding restricted cash, decreased by $130.3 million when compared to t...

- Reported positive preclinical data for its next-generation KRAS G12C GTP/GDP dual inhibitor development candidate, BBO-8520, and for its novel PI3Kα:RAS breaker mechanism in late lead optimization - Reported positive updated 12-month Phase 2 data for BBP-4...

- BridgeBio to host investor call today (October 17, 2022) at 1:30 pm ET to discuss its two most advanced RAS precision oncology programs – KRAS G12C GTP/GDP dual inhibitor development candidate BBO-8520, and its novel PI3Kα:RAS breaker mechanism ...

Summary China pharma company Jinxi Jemincare out-licensed global rights for its androgen receptor degrader to Roche in a $650 million agreement. The oral small-molecule candidate, developed in Jemincare’s R&D center, is currently in preclinical testing. Shanghai IASO Bi...

Updated data from a phase 2 trial found that BridgeBio Pharma's ( NASDAQ: BBIO ) BBP-418 led to i mprovements over 12 months in those with limb-girdle muscular dystrophy type 2i (LGMD2i) . Results showed that after 12 months of treatment, there was increased glycosylat...

Novel assay developed to assess the extent of alpha-dystroglycan ( ⍺ DG) glycosylation, the core pathology of LDMD2i, from muscle biopsy samples Increase in the ratio of glycosylated αDG to total αDG from baseline towards normal levels, suggestin...

- Robust post-dosing changes continue to be seen in key markers associated with severity of disease - Pharmacodynamic data from the first three participants show sustained reductions in N-acetylaspartate (NAA) in the brain and urine, suggesting that the investigational therapy i...

BridgeBio Pharma ( NASDAQ: BBIO ) stock rose ~4% on Oct. 11 after the company said the the U.S. Food and Drug Administration (FDA) granted fast track designation to BBP-398 in combination with Amgen's ( NASDAQ: AMGN ) Lumakras for adult patients with previously...

- BBP-398, an investigational SHP2 inhibitor, is a potentially optimal agent for use in combination therapies given its continuous, once-daily dosing in addition to synergistic activity with other agents to treat cancers driven by KRAS G12C mutations - The combination of investi...